PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2014 | 1 | 1 |
Tytuł artykułu

Hyperammonemia, an under-recognized complication and adverse prognostic marker in Multiple Myeloma

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Hyperammonemia, a well-known complication of liver failure causing encephalopathy, has rarely been reported as a complication of multiple myeloma. We report four additional cases of hyperammonemia in patients with treatment refractory multiple myeloma. In these cases, we found that hyperammonemia remains a morbid complication of resistant disease without directed myeloma therapy. Our brief review has reaffirmed that hyperammonemia is a poor prognostic marker in myeloma with an undetermined mechanism. This complication’s poor response to traditional therapies, including rifaximin and lactulose, prompts our discussion urging early recognition and myeloma directed therapy. Clinical observations may support that proteasome inhibitors may be most effective in the treatment of these patients.
Wydawca

Rocznik
Tom
1
Numer
1
Opis fizyczny
Daty
otrzymano
2015-05-16
zaakceptowano
2015-09-10
online
2016-01-06
Twórcy
  • Hematology/
    Oncology Fellow, Department of Hematology & Oncology, Rutgers
    Robert Wood Johnson Medical School, 125 Paterson Street, Suite
    5200, New Brunswick, NJ 08901,
  • Associate Professor of Medicine, Department of
    Medical Oncology, Rutgers Cancer Institute of New Jersey, 195 Little
    Albany Street, New Brunswick, NJ 08901
  • Assistant Professor of Medicine, Division Chief
    and Program Director Hematology & Oncology, Drexel University
    College of Medicine, 230 North Broad Street, 15th Floor South Tower
    Philadelphia, PA 19102
Bibliografia
  • [1] Lora-Tamayo J, Palom X, Sarra J, Gasch O, Isern V, Fernandezde Sevilla A, et al. Multiple myeloma and hyperammonemicencephalopathy: review of 27 cases. Clinical lymphoma &myeloma. 2008;8(6):363-9.[WoS][Crossref]
  • [2] Furer V, Heyd J. Hyperammonemic encephalopathy in multiplemyeloma. The Israel Medical Association journal : IMAJ.2007;9(7):557-9.
  • [3] Benet B, Alexandra JF, Andrieu V, Sedel F, Ajzenberg N,Papo T. Multiple myeloma presenting as hyperammonemicencephalopathy. Journal of the American Geriatrics Society.2010;58(8):1620-2.[Crossref]
  • [4] Howman R, Thakerer A, Pitman M, Ding N, Thompson PA, KhotA, et al. Bortezomib, cyclophosphamide, and dexamethasone:highly effective for rapid reversal of myeloma-associatedhyperammonemic encephalopathy. Leukemia & lymphoma.2010;51(12):2299-302.
  • [5] Pham A, Reagan JL, Castillo JJ. Multiple myeloma-inducedhyperammonemic encephalopathy: an entity associatedwith high in-patient mortality. Leukemia research.2013;37(10):1229-32.[Crossref][WoS]
  • [6] Jones FM, Bokhari SW. Hyperammonemic encephalopathy inmultiple myeloma. Annals of hematology. 2014;93(8):1431-2.[WoS]
  • [7] Ikewaki J, Ogata M, Imamura T, Kohno K, Nakayama T, Kadota J.Development of hyperammonemic encephalopathy in patientswith multiple myeloma may be associated with the appearanceof peripheral blood myeloma cells. Leukemia & lymphoma.2009;50(4):667-9.
  • [8] Ichikawa A, Hashimoto A, Shimizu A, Shizuku J, Abe Y, WakaiS, et al.
  • [A case of acute renal and liver dysfunction withlight chain deposition disease]. Nihon Jinzo Gakkai shi.2007;49(4):459-63.[PubMed]
  • [9] Shah AS, Shetty N, Jaiswal S, Mehta BC. Hyperammonemia: anunusual presenting feature of multiple myeloma. Indian journalof medical sciences. 2005;59(1):24-7.
  • [10] Minauchi K, Fujie T, Matsubara N, Kasahara H, Ogura Y, TamuraM, et al.
  • [Primary plasma cell leukemia (IgD-lambda) withhyperammonemia]. Nihon Naika Gakkai zasshi The Journal ofthe Japanese Society of Internal Medicine. 2004;93(1):139-41.
  • [11] Holahan JR. Hyperammonemia: elevated ammonia levelsin multiple myeloma. The American journal of medicine.2004;116(3):210-1.
  • [12] Kozuka T, Fukuda S, Imai T, Sezaki T.
  • [Clinical significance of amultiple myeloma cell line, derived from a case associated withhyperammonemia]. [PubMed]
  • [Rinsho ketsueki] The Japanese journal ofclinical hematology. 2000;41(11):1220-5.[PubMed]
  • [13] Matsuzaki H, Uchiba M, Yoshimura K, Yoshida M, Akahoshi Y,Okazaki K, et al. Hyperammonemia in multiple myeloma. Actahaematologica. 1990;84(3):130-4.[Crossref][WoS]
  • [14] Martinelli G, Peccatori F, Ullrich B, Ghielmini M, RoggeroE, Goldhirsch A. Clinical manifestation of severe hyperammonaemiain patients with multiple myeloma. Annals ofoncology : official journal of the European Society for MedicalOncology / ESMO. 1997;8(8):811.
  • [15] Frere P, Canivet JL, Gennigens C, Rebeix JP, Fillet G, BeguinY. Hyperammonemia after high-dose chemotherapy andstem cell transplantation. Bone marrow transplantation.2000;26(3):343-5.
  • [16] James JH, Ziparo V, Jeppsson B, Fischer JE. Hyperammonaemia,plasma aminoacid imbalance, and blood-brain aminoacidtransport: a unified theory of portal-systemic encephalopathy.Lancet. 1979;2(8146):772-5.[Crossref]
  • [17] Brucculeri M, Gabbard W, Masson J, Jooma N. Simultaneousdouble hemodialysis for the control of refractory hyperammonemia.The International journal of artificial organs.2013;36(2):135-8.[WoS]
  • [18] Otsuki T, Yamada O, Sakaguchi H, Ichiki T, Kouguchi K, Wada H,et al. In vitro excess ammonia production in human myelomacell lines. Leukemia. 1998;12(7):1149-58.[Crossref]
  • [19] Matsuzaki H, Hata H, Sonoki T, Matsuno F, Kuribayashi N,Yoshida M, et al. Serum amino acid disturbance in multiplemyeloma with hyperammonemia. International journal ofhematology. 1995;61(3):131-7.
  • [20] Kuribayashi N, Matsuzaki H, Hata H, Yoshida M, Sonoki T,Nagasaki A, et al. Multiple myeloma associated with serumamino acid disturbance and high output cardiac failure.American journal of hematology. 1998;57(1):77-81.
  • [21] Martin SK, Diamond P, Gronthos S, Peet DJ, Zannettino AC. Theemerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.Leukemia. 2011;25(10):1533-42.[WoS]
  • [22] Watson AJ, Chambers T, Karp JE, Risch VR, Walker WG, BrusilowSW. Transient idiopathic hyperammonaemia in adults. Lancet.1985;2(8467):1271-4.[Crossref]
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_1515_cdth-2015-0003
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.